RECEPTOL® - Efficacy Test Report
RECEPTOL® EFFICACY TEST REPORT
1. RECEPTOL’S® Mode of Action
RECEPTOL’S® Info-protein matrix works:
- The small molecular weight proteins called peptides act as attachment inhibitors, by docking on the CD4 GP-120 receptor site preventing the attachment of HIV.
- Once docked on CD4 GP-120 receptor site, it sends a signal telling the other CD4 T- cells to “lock-down” and not allow HIV to attach.
- In the first 30-60 days the viral load may increase, because it cannot attach.
- CD4 T-cells will also begin to increase in the first 30-60 days.
- The viral load will begin to decrease significantly from 60 days on, and go undetected in 180-210 days.
2. Intra-Oral Absorption
The reason Intra-Oral is so fast, is the flow of absorbed nutrients from this area of the mouth is to the Carotid Artery, this is the large artery that supplies blood to the brain and the heart. Absorption through this method supplies nutrients to the brain and the heart within 22 to 30 seconds! Within minutes, it is totally dispersed throughout the body.
The Absorption Effectiveness Chart on this page is based on the authoritative Physician's Desk Reference Manual and clearly illustrates the difference in absorption by various means. Oral Absorption through the mucosa (the lining of the mouth) is the preferred choice of medical experts, and provides up to 9-times more effective absorption into the bloodstream... within just seconds.
Oral absorption is the preferred choice of medical experts for the administration of nutrients and drugs over the orally swallowed tablet or pill, thus avoiding the gastrointestinal tract and its many limitation." - Introduction to Pharmaceutical Dosage Forms (Howard C. Ansel, Ph.D., Second Edition, 1976).
"When DHEA is swallowed in a capsule, it first must pass through the liver before it can reach the body. The liver may metabolize up to 90% of the DHEA before it reaches the rest of the body. By opening the capsule, and holding the powder under your tongue before swallowing, you will get rapid absorption into your brain where it can produce neurological protection and enhancement."
- Life Extension Foundation Newsletter, July 1996.
"... asthmatics who use inhaled steroids are half as likely to be hospitalized as those who use other (forms of) - or no - medication." - 16,941 HMO enrollee study published in JAMA.
3. Evidence of Non-recurrence of HIV after the treatment is stopped.
Phase 3 – HIV trial
In November 2002, Phase 3 of the study on HIV began in Rwanda. The protocol was similar to that which was employed in Phase 1 and Phase 2.
Objectives: To demonstrate, under clinical conditions, the safety and efficacy of infoprotein supplementation in patients known to have advanced disease (HIV/AIDS). Cohorts were all symptomatic, ambulatory, compliant and native to anti-retroviral therapy.
Limitations: The transient nature of the cohort population and minimal control of product use.
Population: 60 cohorts, term: 365 days and moderate control of product use.
Considerations: All cohorts receive oral supplementation of RECEPTOL® every 6 hours for a period of 365 days.
25
Some patients could not refrigerate the product after opening, therefore exposing it to the denaturing effect of bacterial contamination.
The patients were not made aware of the positive potential of the product.
Results:· The product appeared to be free of side effects and generally well tolerated by the participants. Some signs, consistent with detoxification, were noted but resolved when the patients increased their water consumption.
- The product demonstrated significant value by reducing or resolving the symptoms of opportunistic infections most commonly associated with the dynamic of HIV/AIDS.
- Patients often experienced weight gains as part of an overall pattern of positive response.
- After 1 day of use there was a moderate level of relief of fever and diarrhea.
- After 14 days of use all patients experienced relief of skin lesions, mouth thrush, fever, diarrhea, tuberculosis.
- After 90 days of use all patients experienced relief of all symptoms.
- After 330 days all patients are still not experiencing any negative symptoms.
Discussion:
In brief, the patients recovered very quickly but complain of INTENSE HUNGER AND THIRST. It is VITAL TO INTERVENE BY GIVING PROTEIN SUPPLIMENTATION to be able to observe the body reconstruction as most patients are very poor and have low protein intake. Generally speaking there is an excellent recovery for all patients that have been on the product but the EXTREME HUNGER is hindering the weight gain process. – Dr. Rusibira, Internal Medicine Specialist.
Summary:
Positive clinical results are continually observed in the Rwanda patients.
4. Control: Positive & Negative
All subjects were given the RECEPTOL® in the East African study. There wasn’t a control group given a placebo or another HIV/AIDS drug. There were no side effects reported other then increase appetite, energy and hopefulness.
5. Can a healthy person take it as a prophylaxis, prevention for HIV?
At this time we are uncertain that RECEPTOL® can be used as a prophylaxis for HIV. Theoretically, because of the mode of operation, one can surmise that it may very well work as an effective prophylaxis. We would entertain the idea of further clinical trials to find the answer.